Inactivated flu vaccine market seen reaching $10.55 billion by 2030

The inactivated influenza vaccine market is projected to grow from $7.14 billion in 2025 to $10.55 billion by 2030, driven by broader immunization programs, higher flu awareness and investment in newer vaccine technologies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - The inactivated influenza vaccine market is expanding as governments, health systems and manufacturers push to reduce the impact of seasonal flu. - Growth in adult and elderly vaccination, pandemic preparedness and new vaccine technologies could reshape how flu shots are made and distributed.

What happened: - The Business Research Company projected the global inactivated influenza vaccine market will rise from $7.14 billion in 2025 to $7.72 billion in 2026. - The report forecasts the market will reach $10.55 billion by 2030, at an 8.1% CAGR. - The company released its Inactivated Influenza Vaccine Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report said North America held the largest regional share in 2025. - The report said Asia-Pacific is expected to be the fastest-growing region over the forecast period. - A free sample of the report is available. - The full market report is also available.

The details: - Inactivated influenza vaccines use killed or inactivated viruses, which cannot cause disease. - The vaccines are typically given by injection and prompt the immune system to produce antibodies against seasonal flu. - The report linked historical growth to rising seasonal influenza cases, broader immunization programs, stronger preventive health awareness, continued egg-based vaccine production and expanded public health campaigns. - The forecast period is expected to benefit from pandemic preparedness spending, investment in cell-based and recombinant vaccine technologies, broader coverage for adults and the elderly, higher government procurement and manufacturing innovation. - Key trends identified in the report include wider use of quadrivalent vaccines, more high-dose and adjuvanted formulations, longer seasonal vaccination programs, better cold-chain logistics and efforts to scale production efficiently. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also highlighted market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The NHS in the United Kingdom launched a vaccine strategy in December 2023 aimed at improving immunization goals. - The NHS plan focused on community-based vaccination efforts and underserved and marginalized groups.

Between the lines: - Government vaccination programs are becoming a major demand driver because they expand access and reduce out-of-pocket cost for higher-risk groups. - The shift toward newer vaccine formats suggests manufacturers are betting on more precise targeting, better dose performance and broader production capacity. - Regional growth patterns point to mature demand in North America and faster expansion potential in Asia-Pacific as immunization coverage widens.

What's next: - More vaccine procurement by governments could support steady market expansion through 2030. - Wider adoption of newer technologies such as cell-based and recombinant vaccines may change the competitive mix in the flu vaccine market. - Manufacturing and logistics improvements could become key differentiators as producers try to scale output more efficiently.

The bottom line: - The inactivated flu vaccine market is on track for sustained growth, with public immunization policy and next-generation vaccine development driving the next phase of expansion.